CD274 and neoplasm: AXL may contribute to an immune-evasive TME by impairing antigen presentation (12–14), increasing PD-L1 expression on cancer cells (15, 16), enabling intrinsic cancer cell-resistance to immune-mediated killing (17), and altering the cytokine profile in the TME to be more tumor-supportive (18).